Author(s): B. Shankari, M. Rambabu, S. Jayanthi

Email(s): jayanthi.s@vit.ac.in.

DOI: 10.5958/0974-360X.2018.00652.2   

Address: B. Shankari, M. Rambabu, S. Jayanthi*
Computational Drug Design Lab, School of Bio Sciences and Technology, VIT University, Vellore-632014,Tamil Nadu, India.
*Corresponding Author

Published In:   Volume - 11,      Issue - 8,     Year - 2018


ABSTRACT:
Claudin(CLDN) family proteins are highly involving in human cancer in lung cancer, hepatocellular carcinoma and breast cancer. Hepatocellular carcinoma is initiated due to dysregulation of CLDN-10. It’s also called as malignant hepatoma, the most well-known types of liver cancer. Hence, we aim to propose lead compounds for CLDN-10 inhibition by computational approach. We performed computational workflow using PyRx and AutoDock for virtual screening and docking. In this study, the modelled structure of CLDN-10 is used as target and alfalfa compounds as the ligand dataset. Ligands were docked into active site of CLDN-10 based on structure based drug design. Moreover,virtual screening was done for all 18 compounds of alfalfa ayurvedic plant. Furthermore, we found one best molecule eriodictyol as the top lead with least binding affinity and high number of hydrogen bonds in binding site with the help of docking. This computational study reports eriodictyol as potential lead compound from alfalfa ayurvedic plant. This study provides more insights on the inhibition mechanism of CLDN-10 with lead candidate eriodictyol and further experimental studies can initiate specific hepatocellular carcinoma drug.


Cite this article:
B. Shankari, M. Rambabu, S. Jayanthi. Identification and Designing Inhibitors for Hepatocellular Carcinoma by Targeting Claudin-10. Research J. Pharm. and Tech 2018; 11(8): 3529-3533. doi: 10.5958/0974-360X.2018.00652.2


Recomonded Articles:

Author(s): Zeinab A. Salama, Ahmed M. Aboul-Enein, Alaa A. Gaafar, Mohsen S. Asker, Hanan F. Aly, Habiba A. Ahmed

DOI: 10.5958/0974-360X.2020.00132.8         Access: Closed Access Read More

Author(s): Perumal S, Langeswaran K

DOI: 10.5958/0974-360X.2020.00308.X         Access: Closed Access Read More

Author(s): Rahamat Unissa, Devaragattu Bhargav Varma, Naga Santhosh Kesana, Chekalta Srinivas, Baddanapally Shalem Raj

DOI: 10.5958/0974-360X.2018.00409.2         Access: Open Access Read More

Author(s): Shikha Saxena, Sohini Singh, Sandhya Bawa, Deepshikha Pande Katare

DOI: 10.5958/0974-360X.2019.00607.3         Access: Open Access Read More

Author(s): Rakesh N Pillai, Beny Baby, AJM Christina, Abin Abraham

DOI:         Access: Open Access Read More

Author(s): Soumya Chatterjee, Riddhi Datta, Anwesha Dey, Prakash Pradhan, Krishnendu Acharya

DOI: Not Available         Access: Open Access Read More

Author(s): Avinash Suryawanshi, Yadunath Joshi, Ashish Jain, Vilasrao Kadam

DOI: 10.5958/0974-360X.2015.00254.1         Access: Open Access Read More

Author(s): Abhinav Raj Ghosh, K. L. Krishna, Seema Mehdi, Nandini HS, Chandan HM, Bhooshitha AN

DOI: 10.5958/0974-360X.2020.00619.8         Access: Closed Access Read More

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags